Cord colitis syndrome (CCS) is a recently described diarrheal illness of uncertain pathogenesis that affects recipients of umbilical cord blood transplant and is associated with negative cultures. CCS exhibits a peculiar histopathologic appearance, as it commonly manifests as granulomatous inflammation involving the upper and lower gastrointestinal tract, with features of chronicity in the colon. Importantly, the treatment for CCS differs from that for acute graft-versus-host disease, which is commonly in the clinical differential diagnosis: CCS responds to antibiotic treatment, whereas acute graft-versus-host disease responds to immunosuppression. We describe here the case of a 36-year-old woman with a history of acute myeloid leukemia who developed refractory diarrhea after cord blood transplant. Endoscopic biopsies of the stomach and colon revealed granulomatous inflammation, consisting of scattered ill-defined aggregates of epithelioid histiocytes, with associated mild neutrophilic inflammation and mildly increased epithelial cell apoptosis. In the colon, the granulomatous inflammation was associated with surface epithelial injury (including surface erosions) and contained occasional multinucleated epithelioid giant cells. Paneth cell metaplasia was present in the distal colon, but crypt architecture was preserved, and there was no basal lymphoplasmacytosis. Special stains and immunohistochemical stains for infectious organisms were negative. A diagnosis of CCS was made, and the patient promptly responded to treatment with ciprofloxacin and metronidazole. We present this case to raise awareness among pathologists of this newly described entity, in order to facilitate its timely diagnosis and treatment.
U mbilical cord blood transplantation (CBT) is an alternative source of hematopoietic cells for individuals who need hematopoietic stem cell transplantation and do not have a matched related or unrelated donor. [1] [2] [3] [4] [5] [6] CBT, when compared with other forms of marrow transplantation, typically results in less severe symptoms of graft-versus-host disease (GvHD). [1] [2] [3] [4] [5] [6] However, a peculiar form of culture-negative, nonsteroid responsive diarrhea in patients who have undergone CBT has recently been described. 7 This diarrheal illness has been termed cord colitis syndrome (CCS) and is associated with a favorable prognosis, as it responds to a short course of antibiotics, although relapse is common. 7 Interestingly, CCS patients commonly exhibit granulomatous inflammation on biopsies from the upper and lower gastrointestinal (GI) tract, as well as features of chronic injury such as Paneth cell metaplasia in the distal colon. 7 The precise pathogenesis of CCS remains unclear at this time but may be related to immunologic and/or microbiological alterations in the gut in the setting of CBT.
We present here the case of a 36-year-old woman with acute myeloid leukemia (AML) who developed CCS after CBT, with characteristic histopathologic findings on endoscopic biopsies from the stomach and colon. We describe this case to increase awareness among pathologists of this newly described condition, in order to promote prompt diagnosis and treatment.
CASE REPORT

Clinical History
A 36-year-old woman with a history of AML was admitted with symptoms of persistent nausea, vomiting, and diarrhea. Her history was significant for induction chemotherapy with daunorubicin and cytarabine 2 years prior. She then received consolidation with etoposide and high-dose arabinofuranosyl cytidine, followed by autologous stem cell transplantation. She did well until 8 months before admission, when she was found to have recurrent AML. She then underwent induction therapy with high-dose cytarabine and consolidation chemotherapy. There were no matched related or unrelated donors. She was subsequently admitted for double CBT. She received a conditioning regimen of fludarabine, melphalan, and total body irradiation and underwent CBT. She then developed engraftment syndrome, which responded to low-dose prednisone therapy.
Two months before admission, she developed symptoms of diarrhea and elevated serum transaminases and alkaline phosphatase (aspartate aminotransferase 205 U/L, normal 9 to 32 U/L; alanine aminotransferase 584 U/L, normal 7 to 32 U/L; and alkaline phosphatase 137 U/L, normal 30 to 100 U/L), with a normal bilirubin. Stool studies, including cultures, Clostridium difficile toxin testing, and ova and parasite testing were negative. She was empirically started on steroids for presumed acute GvHD. A flexible sigmoidoscopy was performed up to the splenic flexure and was unremarkable. Colonic biopsies did not show any evidence of acute GvHD and were otherwise unremarkable. A liver biopsy was performed. The biopsy showed moderate to severe iron deposition in a mixed (parenchymal and reticuloendothelial) pattern and scattered ceroid-laden macrophages, consistent with recent injury to hepatocytes. A single small parenchymal granuloma was noted. There was minimal portal and lobular inflammation, with no apoptotic hepatocytes, and unremarkable bile ducts. An immunohistochemical stain for cytomegalovirus was negative, an acid-fast bacilli stain was negative, and in situ hybridization for Epstein-Barr virus-encoded RNA was negative. The findings were considered nonspecific and interpreted as evidence of resolving injury to hepatocytes, possibly related to the use of fluconazole. There was no evidence of acute GvHD.
Repeat upper and lower GI tract endoscopic evaluation with biopsies was then performed. The duodenum showed increased mitoses suggestive of regenerative changes, and the colon showed regenerative colonic mucosa with patchy inflammation and ulceration. The inflammation in the colon was predominantly histiocytic with a few areas of neutrophils. There were no granulomas or viral inclusions and only very rare apoptotic bodies. An immunohistochemical stain for cytomegalovirus was negative. The findings were considered nonspecific with possible etiologies including an infectious or drug exposure. After several days of nonresponse to steroids, the patient was given an empiric trial of antibiotics and had improvement in her diarrhea. The serum transaminases improved with cessation of fluconazole. Her dose of sirolimus was also adjusted for the appropriate level of immunosuppression.
A follow-up bone marrow biopsy was unremarkable and consistent with remission of disease. The patient was then started on sorafenib, a small molecule inhibitor of several tyrosine kinases, per a study protocol. Two weeks before admission, the patient started to experience refractory symptoms of nausea, vomiting, and diarrhea. Her symptoms were so severe that she required initiation of total parenteral nutrition. She had no other risk factors for her symptoms on the basis of review of her medication list or social history. Her physical examination was also unremarkable. Stool studies were negative for infectious etiologies. The remainder of her laboratory tests, including liver function tests, was all within normal limits. She was subsequently admitted because of her continued symptoms and was empirically started on steroids for presumed acute GvHD.
An upper endoscopy was performed and revealed a normal esophagus, a diffuse moderate gastritis, and a normal duodenum. Biopsies were taken from the stomach and duodenum. A colonoscopy was performed and revealed a diffuse area of moderately erythematous mucosa with superficial erosions in the rectum, sigmoid, and descending colon (Fig. 1A) . The procedure was intentionally stopped at the descending colon, and biopsies were obtained from the sigmoid colon and rectum.
Histopathologic Findings
The stomach and colonic biopsies both exhibited patchy lymphohistiocytic to granulomatous inflammation, consisting of ill-defined aggregates of epithelioid histiocytes (Fig. 1) . The inflammation was centered within the lamina propria but was associated with occasional foci of neutrophilic cryptitis/ "glanditis" and epithelial cell injury. The changes were more prominent in the colon, which also exhibited multinucleated epithelioid giant cells. Mildly increased epithelial cell apoptosis was noted in the areas of inflammation; however, this was not a prominent feature. Other reactive epithelial changes were noted in both the stomach and colon, including increased mitotic activity and mucin depletion. In the colon, the granulomatous inflammation was associated with surface epithelial injury, including occasional erosions (Fig. 1) . The inflammation, however, was not exclusively superficial, as it was also seen in a basal location. Paneth cell metaplasia was present in the colon (Fig. 1 ). Crypt architecture was preserved, and there was no basal lymphoplasmacytosis. No distinct, well-formed granulomas were seen in any of the biopsies. No viral cytopathic changes were identified. The duodenum was largely unremarkable, with preserved villous architecture, no significant active inflammation, and only rare foci of lymphohistiocytic inflammation.
The following special stains for organisms were negative: acid-fast bacilli, Gomori methenamine silver, periodic acid-Schiff with diastase digestion, Giemsa, and Brown-Hopps. The following immunohistochemical stains for viruses were negative: cytomegalovirus, adenovirus, Herpes simplex virus I and II, and Varicella zoster virus. From a histopathologic standpoint, the differential diagnosis was considered to be broad and included infection, medication effect, and a manifestation of systemic illness. However, given the negative infectious work-up and the clinical context of the case, the findings were judged to be consistent with CCS. The patient was started on intravenous ciprofloxacin and metronidazole with an immediate improvement in her GI symptoms. After a few days, the patient was discharged on a course of oral antibiotics.
DISCUSSION
The development of culture-negative and steroid nonresponsive diarrhea after CBT has been previously described as CCS. This illness is important to distinguish from acute GvHD, as the symptoms overlap but the treatment is different: CCS responds to antimicrobial therapy, either a combination of fluoroquinolones and metronidazole, as in our patient, or metronidazole alone, 7 whereas GvHD responds to immunosuppression. Given that CCS occurs in patients who have many other potential etiologies for diarrhea, including acute GvHD, infection, or medication effect, it is likely to be underappreciated. For example, the patient described here was admitted on 2 separate occasions with various symptoms, including diarrhea, without an identifiable etiology. We aim to raise awareness of this newly described entity among pathologists, because CCS exhibits relatively characteristic histopathologic features, as recently described by Herrera et al 7 in a case series of 11 patients. Although neither of these features is specific by itself, we believe that in the appropriate clinical scenario, pathologists should be able to recognize this constellation of findings and suggest CCS as the appropriate diagnosis.
In the series by Herrera et al, 7 granulomatous inflammation was present in a majority of patients (64%) Am J Surg Pathol Volume 37, Number 7, July 2013
Cord Colitis Syndrome and could affect both the upper and lower GI tract, as it was observed in the stomach, duodenum, or colon. Surface epithelial injury in the colon was noted in 64% of patients. Neutrophilic cryptitis was seen in all cases and was focal or mild in 72% of cases. Paneth cell metaplasia in the distal colon was very common and was seen in 72% of cases. Basal lymphoplasmacytosis and substantial crypt architectural distortion, however, were rare, as they were noted only in 1 patient each (9%). 7 Mildly increased crypt or gland apoptosis was also common, but was not a prominent feature: 64% of cases exhibited grade 1 apoptosis, and only 1 case (9%) exhibited grade 2 apoptosis. 7 The case described here exhibits each of the histopathologic features identified by Herrera and coworkers as typical of CCS (Table 1) . Given the clinical and pathologic differential diagnosis, we recommend excluding infectious etiologies with available special and immunohistochemical stains. In particular, Whipple disease should be excluded by a periodic acid-Schiff with diastase digestion stain, as some authors have speculated that CCS may represent an atypical presentation of Whipple disease. 8 Although the second set of endoscopic biopsies in our patient showed only subtle nonspecific changes (foci of lymphohistiocytic inflammation and neutrophilic cryptitis in the colon biopsy), in retrospect it appears likely that these were already a manifestation of CCS. Pathologists should therefore raise the possibility of CCS even if the histopathologic features are not well developed. In the case described here, the distal colon exhibited more prominent changes than the stomach. However, we recommend tissue sampling from multiple GI locations when CCS is clinically in the differential, given that findings may be seen in the stomach, duodenum, or colon. 7 Epithelial cell apoptosis is only mildly increased in CCS, which, in conjunction with the other findings seen in CCS, should allow pathologists to distinguish CCS from acute GvHD. 9 Etiologically, however, CCS may possibly overlap with the disease spectrum of acute GvHD, given that there is some suggestion that the use of antibiotics or antifungals improves GI symptoms in acute GvHD. [10] [11] [12] However, definitive treatment of acute GvHD typically requires a form of immunosuppression, 13 which is not required for treatment of CCS. Likewise, some authors have speculated whether CCS represents a form of chronic GvHD. 14 Chronic GvHD may exhibit a range of nonspecific pathologic findings, such as lamina propria fibrosis and crypt architectural irregularity, 15, 16 but it is not known to cause granulomatous inflammation. In the case of our patient, chronic GvHD appears unlikely given that she never had an episode of acute GvHD during her clinical course and lacked features suggestive of GvHD in her liver biopsy. Although the precise nature of CCS remains unclear, we believe that it is reasonable to consider it as a distinct entity because of its predictable histopathologic findings and clinical response to antibiotics.
A drug effect may be in the differential diagnosis, although this should not be favored if there have been no recent changes in medications. In our patient, there was clinical suspicion that sorafenib was contributing to the symptoms of diarrhea, as this has been seen in up to 82% of patients while on sorafenib for hepatocellular disease. [17] [18] [19] However, in our patient, the timing is not supportive of this, as sorafenib was stopped during the patient's hospitalization, and there was no improvement in her symptoms. In addition, the reported histopathologic findings in sorafenib-induced colonic injury are different from those in CCS. Specifically, sorafenib is associated with development of discrete ulcers and perforations with thrombotic occlusion of vessels, presumably indicating an ischemic etiology. [20] [21] [22] Although a contribution of sorafenib to the patient's symptoms cannot be definitively excluded, resolution of the diarrhea after antibiotic treatment strongly supports CCS as the overriding etiology.
It is interesting to speculate whether the small granuloma in the liver biopsy ( Fig. 2 ) and the evidence of hepatocytic injury were also a manifestation of CCS. However, granulomas in the liver may be seen in association with a wide range of etiologies or may simply be an incidental finding. The clinical suspicion that the liver injury was due to fluconazole was supported by improvement in transaminases with drug cessation. In rats, injection of the related antifungal itraconazole is associated with development of granulomas in addition to prominent centrilobular hepatocellular injury. 23 Thus, it is plausible that the liver biopsy findings in our patient may be attributable to fluconazole, although an overlap of CCS remains a possibility. The presence of granulomatous inflammation in conjunction with Paneth cell metaplasia in the distal colon may raise the possibility of idiopathic inflammatory bowel disease (IBD); specifically, Crohn disease. [24] [25] [26] [27] [28] Herrera et al 7 also report the presence of pseudopyloric gland metaplasia in 1 of 2 available terminal ileum biopsies, indicative of a chronic ileitis. However, Paneth cell metaplasia in the distal colon is not specific for IBD, as it may be seen in other conditions that result in chronic injury to the colonic mucosa; for example, it is well recognized to occur in collagenous colitis and lymphocytic colitis. 29, 30 Features more in keeping with IBD-type chronicity (basal lymphoplasmacytosis and substantial crypt architectural distortion) are only rarely seen in the colon in CCS. 7 Similarly, well-formed granulomas are uncommon, and the inflammation is usually lymphohistiocytic to ill-defined granulomatous, as in our case. Overall, we propose that IBD-like features in a patient status post CBT presenting with diarrhea should not dissuade the pathologist from suggesting CCS. The overlap in pathologic features does prompt speculation that CCS results from immunologic alterations similar to those seen in Crohn disease. 31 It would be interesting to see whether patients with CCS are at risk for developing clinicopathologic manifestations of IBD on long-term follow-up. Clearly, further investigation into the pathogenesis and clinical behavior of CCS is needed.
In summary, we present a case of CCS manifesting as granulomatous inflammation in the stomach and colon, in association with mild neutrophilic inflammation, surface erosions, mildly increased apoptosis and Paneth cell metaplasia in the distal colon. We believe that in the appropriate clinical setting, pathologists and clinicians should be able to recognize this constellation of findings as characteristic of CCS. Distinguishing CCS from acute GvHD on the basis of endoscopic biopsies is important in order to allow for timely initiation of antibiotic treatment.
